18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Abstract Background The purpose of the study was to investigate a novel BRAF and CDK 4/6 inhibitor combination therapy in a murine model of BRAF-V600-mutant human melanoma monitored by 18F–FDG-PET/CT and diffusion-weighted MRI (DW-MRI). Methods Human BRAF-V600-mutant melanoma (A375) xenograft-bearin...

Full description

Bibliographic Details
Main Authors: Ralf S. Eschbach, Philipp M. Kazmierczak, Maurice M. Heimer, Andrei Todica, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Georg Keinrath, Olga Solyanik, Jessica Olivier, Wolfgang G. Kunz, Maximilian F. Reiser, Peter Bartenstein, Jens Ricke, Clemens C. Cyran
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Cancer Imaging
Subjects:
Melanoma
BRAF inhibitor
CDK inhibitor
18F–FDG-PET
Diffusion-weighted MRI
Therapy monitoring
Online Access:http://link.springer.com/article/10.1186/s40644-018-0135-y

Internet

http://link.springer.com/article/10.1186/s40644-018-0135-y

Similar Items